Minimally Invasive Adipose-Derived Stem Cell and Platelet-Rich Plasma Therapy for Osteoarthritis and Connective Tissue Degeneration

What this Trial Is About

Researchers are evaluating the use of biocellular and cellular therapies derived from a persons own stemstromal cells combined with platelet-rich plasma PRP to treat osteoarthritis OA and related musculoskeletal aging, pain, and degeneration. This study aims to explore minimally invasive, non-pharmaceutical treatments to relieve OA symptoms and improve joint function, addressing the limitations of traditional surgeries and medical management. The study tracks baseline health and monitors progress over time to understand treatment impact. The trial includes three treatment approaches 1 guided biocellular therapy using tissue stromal vascular fraction tSVF plus PRP concentrate 2 combined biocellular and cellular therapy with tSVF, PRP, and cellular stromal vascular fraction cSVF and 3 cSVF delivered intravenously suspended in sterile normal saline. Treatments involve harvesting stem cells and platelets, guided placement with ultrasound, and systemic infusion. Participants receive one or more treatments, with follow-up tracking to compare outcomes from single versus multiple sites or treatments. Participants will undergo regular assessments including imaging with ultrasound and radiography, pain scales, and joint function questionnaires at baseline, 1 month, 6 months, and up to 2 years post-treatment. Researchers monitor complications, pain changes, and structural joint improvements while participants report any unexpected adverse events. The trial includes long-term follow-up to assess safety and effectiveness of these regenerative therapies for OA and connective tissue degeneration.

Adipose-Derived Biocellular Regenerative Therapy for Osteoarthritis